Regulatory tightening of over-the-counter alcohol-containing medicinal formulations reflects the tension between healthcare access and substance-abuse prevention. Discuss with reference to recent amendments to the Drugs Rules, 1945.

Medicinal formulations like tinctures of cardamom and ginger, some containing 80–90% v/v alcohol, were long exempted from licensing under Schedule K of the Drugs Rules, 1945 (framed under the Drugs and Cosmetics Act, 1940) [1]. Recent amendments withdrawing this exemption expose a genuine trade-off between easy medicine access and curbing misuse.

The substance-abuse prevention case (why tightening was needed)

• High-strength preparations were diverted for intoxication, escaping the regulated supply chain [1].
• The July 2026 amendment shifts formulations with >12% v/v ethyl alcohol in quantities exceeding 30 mL from Schedule K to Schedule H1, mandating sale only against a Registered Medical Practitioner's prescription with record-keeping [1].
• It follows the December 2025 notification (G.S.R. 927(E)) ending the cough-syrup exemption in villages under 1,000 population — a consistent, precautionary tightening [2].

The healthcare-access concern (the cost side)

• Withdrawing village-level exemptions strains last-mile access where licensed pharmacies are scarce [2].
• New licensing raises compliance costs for small manufacturers of genuine formulations [1].
• Enforcement burdens state drug controllers, requiring central–state coordination [1].

Effective regulation must therefore be calibrated, not blunt. Pairing prescription controls with strengthened rural pharmacy networks and awareness would close the misuse loophole while safeguarding legitimate access — advancing SDG-3 (good health) through the balance the Drugs and Cosmetics Act itself envisions: protecting public health without denying medicine.